pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2014-0-1-43-47pulmo-177Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESЭФФЕКТИВНОСТЬ ИСПОЛЬЗОВАНИЯ АТОРВАСТАТИНА В КОМБИНАЦИИ С АМЛОДИПИНОМ У БОЛЬНЫХ ХРОНИЧЕСКОЙОБСТРУКТИВНОЙ БОЛЕЗНЬЮ ЛЕГКИХ С СОПУТСТВУЮЩИМ МЕТАБОЛИЧЕСКИМ СИНДРОМОМEFFICACY OF ATORVASTATIN PLUS AMLODIPINE COMBINATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND COMORBID METABOLIC SYNDROMEСтупницкаяА. Я.StupnitskayaA. Ya.

к. м. н., доцент кафедры внутренней медицины Буковинского ГМУ; тел.: (38 037) 223-32-62

dumanna77@mail.ruБуковинский государственный медицинский университет: 58001, Украина, Черновцы, пл. Театральная, 2Russian Federation201428022014014347Copyright © Ступницкая А.Я., 20142014Ступницкая А.Я.Stupnitskaya A.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/177

Изучалась эффективность использования комбинации аторвастатина и амлодипина у больных хронической обструктивной болезнью легких (ХОБЛ) с сопутствующим метаболическим синдромом (МС). В исследовании приняли участие больные ХОБЛ с сопутствующим МС (n = 32) и без МС (n = 20). Определялись липиды крови, уровни С-реактивного белка (СРБ), лептина и фактора некроза опухоли-a (TNF-a) в сыворотке крови. У больных ХОБЛ + МС через 0,5 года отмечено снижение индекса массы тела, процентного содержанияжировой массы, артериального давления, уровней триглицеридов, холестерина липопротеидов низкой и очень низкой плотности, СРБ и TNF-a, лептина. При использовании аторвастантина и амлодипина у пациентов улучшились липидный обмен, толерантность к физической нагрузке, снизилась воспалительная активность.

The aim of the study was to examine efficacy of atorvastatin plus amlodipine combination in patients with chronic obstructive pulmonary disease (COPD) and metabolic syndrome (MS) as a comorbidity. The study involved 32 patients with COPD and MS and 20 patients without MS. We measured blood concentrations of lipids, C – reactive protein (CRP), leptin and tumor necrosis factor-a (TNF-a). In 6 months, patients with COPD and MS decreased body mass index, fat mass percentage, blood pressure, and blood concentrations of triglycerides, low density and very low density cholesterol, CRP, TNF-a, and leptin. Therefore, atorvastatin plus amlodipine combination improved lipid metabolism and the patients' physical tolerance and reduced inflammation.

хроническая обструктивная болезнь легкихметаболический синдроматорвастатинамлодипинchronic obstructive pulmonary diseasemetabolic syndromeatorvastatinamlodipineReferencesFabbri L.M., Luppi F., Beghe B., Rabe K.F. et al. Complex chronic comorbidities of COPD Eur. Respir. J. 2008; 31 (1): 204–212.Fabbri L.M., Luppi F., Beghe B., Rabe K.F. et al. Complex chronic comorbidities of COPD Eur. Respir. J. 2008; 31 (1): 204–212.Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165–1185.Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165–1185.Magnussen H., Watz Н. Systemic inflammation in COPD and asthma: relation with comorbidities. Proc. Am. Thorac. Soc. 2009; 6: 648–651.Magnussen H., Watz Н. Systemic inflammation in COPD and asthma: relation with comorbidities. Proc. Am. Thorac. Soc. 2009; 6: 648–651.Poulain M., Doucet M., Drapeau V. et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron. Respir. Dis. 2008; 5 (1):35–41.Poulain M., Doucet M., Drapeau V. et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron. Respir. Dis. 2008; 5 (1):35–41.Skyba P., Ukropec J., Pobeha P. et al. Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. Mediat. Inflamm. 2010; 2010: 173498.Skyba P., Ukropec J., Pobeha P. et al. Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. Mediat. Inflamm. 2010; 2010: 173498.Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediat. Inflamm. 2010; 2010: 585989–586000.Tkacova R. Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives. Mediat. Inflamm. 2010; 2010: 585989–586000.Clini E., Crisafulli E., Radaeli A., Malerba M. COPD and the metabolic syndrome: an intriguing association. Intern. Emerg. Med. 2013; 8 (4): 283–289.Clini E., Crisafulli E., Radaeli A., Malerba M. COPD and the metabolic syndrome: an intriguing association. Intern. Emerg. Med. 2013; 8 (4): 283–289.Watz H., Waschki B., Kirsten A. et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039–1046.Watz H., Waschki B., Kirsten A. et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039–1046.Kupeli E., Ulubay G., Ulasli S.S. et al. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 2010; 38 (1): 76–82.Kupeli E., Ulubay G., Ulasli S.S. et al. Metabolic syndrome is associated with increased risk of acute exacerbation of COPD: a preliminary study. Endocrine 2010; 38 (1): 76–82.Patel A.R.C., Hurst S.R. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: stat of the art. Expert Rev. Respir. Med. 2011; 5: 647–662.Patel A.R.C., Hurst S.R. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: stat of the art. Expert Rev. Respir. Med. 2011; 5: 647–662.Chatila W.M., Thomashow B.M., Minai O.A. et al. Comorbidities in COPD. Proc. Am. Thorac. Soc. 2008; 5:449–553.Chatila W.M., Thomashow B.M., Minai O.A. et al. Comorbidities in COPD. Proc. Am. Thorac. Soc. 2008; 5:449–553.Dobler C.C., Wong K.K., Marks G.B. Associations between statins and COPD: a systematic review. BMC Pulm. Med. 2009; 9: 32.Dobler C.C., Wong K.K., Marks G.B. Associations between statins and COPD: a systematic review. BMC Pulm. Med. 2009; 9: 32.Janda S., Park K., Gerald M.F. Statins in COPD. Chest 2009; 136: 734–743.Janda S., Park K., Gerald M.F. Statins in COPD. Chest 2009; 136: 734–743.Young R.P., Hopkins R., Eaton T.E. Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 2009; 18: 222–232.Young R.P., Hopkins R., Eaton T.E. Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 2009; 18: 222–232.Cowan D.C., Cowan J.O., Palmay R. et al. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax 2010; 65: 891–896.Cowan D.C., Cowan J.O., Palmay R. et al. Simvastatin in the treatment of asthma: lack of steroid-sparing effect. Thorax 2010; 65: 891–896.Mortensen E.M., Copeland L.A., Pugh M.J.V. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir. Res. 2009; 10: 45.Mortensen E.M., Copeland L.A., Pugh M.J.V. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir. Res. 2009; 10: 45.Lawes C.M.M., Thornley S., Young R. et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim. Care Respir. J. 2012; 21: 35–40.Lawes C.M.M., Thornley S., Young R. et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim. Care Respir. J. 2012; 21: 35–40.Mancini G.B., Etminan M., Zhang B. et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006; 47: 2554–2560.Mancini G.B., Etminan M., Zhang B. et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006; 47: 2554–2560.Wells C.E., Baker E.H. Metabolic syndrome and diabetes mellitus in COPD. Eur. Respir. Monogr. 2013; 59: 117–134.Wells C.E., Baker E.H. Metabolic syndrome and diabetes mellitus in COPD. Eur. Respir. Monogr. 2013; 59: 117–134.Young R.P., Hopkins R., Eaton T.E. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad. Med. J. 2009; 85: 414–421.Young R.P., Hopkins R., Eaton T.E. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad. Med. J. 2009; 85: 414–421.

The authors declare that there are no conflicts of interest present.